Cartherics is currently undertaking a new capital raise to initiate clinical trials for its lead allogeneic cell therapy for ovarian cancer. CTH-401 is the only NK cell product currently under development that targets the adenocarcinoma specific antigen – TAG-72.
The company is looking to raise up to AU$20 million to support its ongoing development activities and […]
Melbourne, Australia, 28 April 2023 – Cartherics Pty Ltd (“Cartherics”), a biotechnology company developing immune cell therapies for the treatment of cancer, announced today that it has granted Shunxi Holding Group Co Ltd (“Shunxi”) a licence to develop, manufacture and commercialise Cartherics’ autologous CAR-T cell product, CTH-004, for the treatment of multiple solid tumours including […]
Melbourne, Victoria, Australia 27 February 2023
Peter MacCallum Cancer Centre (“Peter Mac”) and Cartherics Pty Ltd (“Cartherics”) announced today they have entered into a Collaborative Development Program Agreement (CDPA) to develop Cartherics’ proprietary autologous CAR-T cell therapy (CTH-004) for the treatment of ovarian cancer.
The clinical trial to be conducted by Peter Mac will be the first […]
Melbourne, Australia, 09 January 2023 – Cartherics Pty Ltd (“Cartherics”), a biotechnology company developing immune cell therapies for the treatment of cancer, announced today that it has been granted Chinese patent ZL 201680069543.6, entitled “Genetically modified cells and uses thereof”. This patent is part of the family represented by the international patent filing WO2017088012.
The […]
Melbourne, Victoria, Australia – 08 November 2022
The Peter MacCallum Cancer Centre (“Peter Mac”) and Cartherics Pty Ltd (“Cartherics”) announced today they have entered into a Collaborative Development Program Agreement (CDPA) to develop Cartherics’ proprietary autologous CAR-T cell therapy (CTH-001) for the treatment of cutaneous T-cell lymphoma (CTCL).
“Patients with advanced stages of cutaneous T-cell lymphomas often […]
MELBOURNE, Australia, 13 October 2022 – Cartherics, a biotechnology company developing immune cell therapies for the treatment of cancer, has opened today a brand-new state-of-the-art facility to strengthen the company’s research and manufacturing capabilities, as well as support local innovation. Cartherics invested AU$4M in the newly designed and built facility, which includes PC2 and dedicated […]
MELBOURNE, Australia, 27 September 2022 – Cartherics, a biotechnology company developing immune cell therapies for the treatment of cancer, together within partner institutions, has received $5.4M Medical Research Futures Fund (MRFF) grant to develop a new approach to enhance cancer therapy by engaging the patients’ own immune system to complement CAR cell therapy.
The company, in […]
On Thursday, 2 September, in an interview with Jack Hodgins on 2NUR.FM’s ‘Wellbeing’ segment, Professor Bryan Williams (Cartherics Non-Executive Board Member) spoke about COVID-19, viruses and how vaccines control them, and the importance of medical research.
“I would encourage Australians to convince their politicians that they need to increase the research budget in Australia, […]
Cartherics Pty Ltd and the Australian Regenerative Medicine Institute (ARMI), including commercialisation initiative CCRM Australia, announced agreements for closer cooperation and collaboration today.
“Cartherics affiliation with ARMI is an important step in our development and will embed industry and academic excellence in regenerative medicine and translation to clinical medicine in cancer,” said Prof Alan Trounson, Cartherics […]
Melbourne, Australia and Seoul, South Korea
28 June 2021
Cartherics Pty Ltd (“Cartherics”) and ToolGen, Inc. (“ToolGen”) announced today that they have entered into a commercial licence agreement.
Under the agreement, Cartherics obtains […]
Cartherics’ mission is the development of novel, immune cell therapy products for the treatment of cancer, endometriosis and Alzheimer’s disease.
Stay informed about our latest news and developments
© Copyright 2022 | Cartherics Pty ltd
